Analysts Issue Forecasts for TVTX FY2030 Earnings

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Investment analysts at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for shares of Travere Therapeutics in a research note issued on Wednesday, January 14th. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings of $7.33 per share for the year. HC Wainwright currently has a “Buy” rating and a $47.00 target price on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($1.40) per share.

Travere Therapeutics (NASDAQ:TVTX) last announced its quarterly earnings results on Thursday, October 30th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.59. The business had revenue of $164.86 million for the quarter, compared to the consensus estimate of $106.09 million. Travere Therapeutics had a negative net margin of 20.32% and a negative return on equity of 178.68%. Travere Therapeutics’s revenue for the quarter was up 162.1% on a year-over-year basis. During the same period last year, the company posted ($0.70) EPS.

TVTX has been the subject of several other reports. Zacks Research downgraded Travere Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 12th. Cowen reaffirmed a “buy” rating on shares of Travere Therapeutics in a research note on Friday, October 31st. Piper Sandler raised their price objective on shares of Travere Therapeutics from $26.00 to $35.00 and gave the stock a “neutral” rating in a report on Tuesday, November 4th. Citigroup increased their target price on Travere Therapeutics from $34.00 to $48.00 and gave the stock a “buy” rating in a report on Friday, October 31st. Finally, TD Cowen boosted their price target on Travere Therapeutics from $30.00 to $40.00 and gave the company a “buy” rating in a report on Friday, October 31st. Thirteen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $38.86.

Travere Therapeutics Trading Down 1.5%

Shares of NASDAQ TVTX opened at $28.49 on Thursday. The stock has a market cap of $2.55 billion, a price-to-earnings ratio of -27.23, a P/E/G ratio of 1.03 and a beta of 0.85. Travere Therapeutics has a twelve month low of $12.91 and a twelve month high of $42.13. The company has a quick ratio of 2.71, a current ratio of 2.75 and a debt-to-equity ratio of 4.23. The company’s fifty day moving average is $35.52 and its 200-day moving average is $26.29.

Institutional Investors Weigh In On Travere Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in TVTX. Capital Fund Management S.A. acquired a new position in shares of Travere Therapeutics during the 2nd quarter worth $1,501,000. Squarepoint Ops LLC boosted its position in Travere Therapeutics by 98.7% during the 2nd quarter. Squarepoint Ops LLC now owns 479,394 shares of the company’s stock worth $7,095,000 after buying an additional 238,070 shares during the period. Voya Investment Management LLC grew its holdings in Travere Therapeutics by 16.2% during the 3rd quarter. Voya Investment Management LLC now owns 194,854 shares of the company’s stock worth $4,657,000 after acquiring an additional 27,133 shares during the last quarter. Y Intercept Hong Kong Ltd grew its stake in shares of Travere Therapeutics by 343.7% in the second quarter. Y Intercept Hong Kong Ltd now owns 68,000 shares of the company’s stock worth $1,006,000 after purchasing an additional 52,675 shares during the last quarter. Finally, Hussman Strategic Advisors Inc. acquired a new stake in Travere Therapeutics during the 2nd quarter valued at approximately $2,486,000.

Insider Transactions at Travere Therapeutics

In related news, insider William E. Rote sold 60,000 shares of the firm’s stock in a transaction on Wednesday, December 24th. The shares were sold at an average price of $40.10, for a total value of $2,406,000.00. Following the completion of the transaction, the insider directly owned 101,443 shares of the company’s stock, valued at approximately $4,067,864.30. This trade represents a 37.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Sandra Calvin sold 67,115 shares of the business’s stock in a transaction dated Tuesday, November 4th. The stock was sold at an average price of $36.00, for a total transaction of $2,416,140.00. Following the transaction, the chief accounting officer owned 48,545 shares in the company, valued at $1,747,620. This represents a 58.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 323,226 shares of company stock valued at $11,290,656. 4.19% of the stock is owned by insiders.

About Travere Therapeutics

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.